BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 15630746)

  • 1. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
    Sarwar H; McGrath H; Espinoza LR
    J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of neuro-Behçet's disease: an update.
    Borhani Haghighi A
    Expert Rev Neurother; 2009 Apr; 9(4):565-74. PubMed ID: 19344307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
    Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
    BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
    Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
    J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
    Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
    Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.
    Olivieri I; Latanza L; Siringo S; Peruz G; Di Iorio V
    J Rheumatol; 2008 May; 35(5):930-2. PubMed ID: 18464316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE; Monaghan TM; Bamford JM
    Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.
    Borhani Haghighi A; Safari A
    Clin Neurol Neurosurg; 2008 Mar; 110(3):315-6. PubMed ID: 18053588
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab.
    Geissal ED; Wernick R
    J Clin Rheumatol; 2010 Jun; 16(4):185-7. PubMed ID: 20414125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Behçet's disease: from hippocrates to TNF-alpha-blockers].
    Zuber PJ; Bart AP; Leimgruber A; Spertini F
    Rev Med Suisse; 2008 Apr; 4(154):1045-8, 1050-4. PubMed ID: 18557534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].
    Lestre S; Trindade F; Martins A; Baptista J; Feio AB; Lopes MJ
    Acta Reumatol Port; 2009; 34(4):633-40. PubMed ID: 20852576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
    Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
    Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF levels of cytokines in neuro-Behçet's disease.
    Borhani Haghighi A; Ittehadi H; Nikseresht AR; Rahmati J; Poorjahromi SG; Pourabbas B; Nazarinia MA; Habibagahi Z; Fattahi MJ; Ghaderi A
    Clin Neurol Neurosurg; 2009 Jul; 111(6):507-10. PubMed ID: 19303205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of genital ulcers with infliximab in Behcet's disease.
    Haugeberg G; Velken M; Johnsen V
    Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.